Cosentyx Drug

Cosentyx Drug Market Outlook

The global Cosentyx drug market is expected to reach a valuation of approximately USD 10 billion by 2033, with a compound annual growth rate (CAGR) of around 8% during the forecast period from 2025 to 2033. This growth is primarily driven by the rising prevalence of autoimmune diseases such as psoriasis and ankylosing spondylitis, alongside a growing awareness of the efficacy of monoclonal antibodies in treatment. Furthermore, the increasing number of approvals and advancements in drug formulations are expected to enhance market penetration. In addition, the expanding healthcare infrastructure and the growth of telemedicine are contributing positively to the market dynamics. As a result, stakeholders are keenly interested in tapping into this lucrative market, paving the way for innovation and enhanced treatment options.

Growth Factor of the Market

The Cosentyx drug market is bolstered by several key factors that contribute to its significant growth. First and foremost, the rising incidence of autoimmune diseases, particularly psoriasis and psoriatic arthritis, has created a substantial demand for effective treatment options. The increasing prevalence of these conditions can be attributed to factors such as environmental triggers, lifestyle changes, and genetic predisposition, leading to a larger patient base seeking effective therapies. Furthermore, the increased focus on biologic therapies, which include monoclonal antibodies like secukinumab, has shifted treatment paradigms towards personalized medicine, enhancing patient outcomes. Another important growth factor is the advancements in biopharmaceutical technologies that have improved drug delivery systems and patient adherence, making treatments more accessible and effective. Moreover, the expansion of reimbursement policies for biologic therapies is making treatments more affordable for patients, thereby boosting market growth. Lastly, ongoing clinical trials and research are continually uncovering new applications for Cosentyx, solidifying its position in the therapeutic landscape.

Key Highlights of the Market

• Projected market valuation of USD 10 billion by 2033 with an 8% CAGR.
• Increasing incidence of psoriasis and related autoimmune disorders driving demand.
• Growing acceptance and integration of biologics in treatment regimens.
• Advancements in drug formulation and delivery systems enhancing patient outcomes.
• Supportive reimbursement policies improving accessibility to treatment options.

By Product Type

Injection:

Injection is the primary product type in the Cosentyx drug market, accounting for a significant share due to its direct administration into the bloodstream, which enables rapid action and effectiveness. Secukinumab, the active ingredient in Cosentyx, is typically administered as a subcutaneous injection, which can be conveniently self-administered by patients at home after the initial doses are provided in a clinical setting. This convenience significantly enhances patient adherence and satisfaction, leading to better treatment outcomes. The injection form is particularly preferred for chronic conditions such as psoriasis and psoriatic arthritis, where regular dosing is crucial for maintaining disease control. The market for injectable formulations is expected to grow as more patients become educated about the benefits of biologics and as healthcare practitioners continue to recommend these therapies for their efficacy.

Tablet:

While Cosentyx is primarily known for its injectable formulation, the tablet segment is gaining attention as pharmacologists explore various delivery methods that could enhance patient compliance. Tablets offer a more traditional approach to medication, which can be appealing to patients who are averse to injections. Research and development are underway to potentially formulate secukinumab in oral dosage forms, which could broaden the treatment options available to patients. This anticipated transition to oral forms could significantly enhance market penetration, particularly among populations that prefer non-invasive treatment modalities. Moreover, the convenience of tablets in terms of storage, portability, and ease of use further positions this product type as a favorable option in the future landscape of the Cosentyx market.

Cream:

The cream formulation of Cosentyx is another product type that targets localized skin conditions like plaque psoriasis. Topical applications are often preferred by patients due to their ease of use and less invasive nature compared to injections. Creams can provide patients with direct relief from symptoms and are particularly effective for individuals with mild to moderate psoriasis. The growth of the cream segment is supported by increasing patient awareness about topical treatments and their role in managing skin symptoms without systemic involvement. As research continues to validate the efficacy of topical biologics, including secukinumab-based creams, this segment is expected to witness growth among patients seeking localized treatment solutions.

Spray:

Spray formulations represent an innovative approach to drug delivery, facilitating ease of use and patient compliance. While not commonly associated with Cosentyx currently, the potential for spray-based delivery systems is being explored, particularly for conditions where targeted application can enhance the therapeutic effect. The development of sprays could offer quick absorption through the skin, beneficial for patients who prefer rapid administration without the need for injections. If successfully developed, spray formulations could expand the market for Cosentyx by appealing to a demographic that values convenience and speed in their treatment regimens.

Patch:

The patch segment presents an intriguing opportunity within the Cosentyx drug market, particularly for patients requiring consistent and controlled delivery of medication. Transdermal patches can provide sustained release of secukinumab, allowing for longer intervals between doses and improving patient adherence. This mode of delivery overcomes some of the challenges associated with injections, such as fear of needles and the need for regular visits to healthcare facilities. The use of patches may also reduce the incidence of systemic side effects by localizing treatment. As innovations in transdermal technology continue to evolve, the patch segment could experience significant growth as a viable alternative for delivering Cosentyx to patients suffering from chronic autoimmune conditions.

By Application

Psoriasis:

Psoriasis stands as one of the most significant applications for Cosentyx, representing a large portion of its market share. This chronic autoimmune condition is characterized by the rapid proliferation of skin cells, leading to red, scaly patches that can cause discomfort and affect quality of life. Cosentyx effectively targets the underlying inflammatory processes associated with psoriasis through its mechanism of action, inhibiting interleukin-17A, a key cytokine involved in the pathogenesis of the disease. The increasing prevalence of psoriasis, coupled with a growing understanding of the condition's impact on mental health, has spurred demand for effective treatments like Cosentyx. The application of this drug in managing psoriasis is expected to expand further as awareness and diagnosis of the condition improve, and as more patients seek out advanced therapeutic options.

Psoriatic Arthritis:

Another significant application of Cosentyx is in the treatment of psoriatic arthritis, a condition that manifests as inflammation and pain in the joints associated with psoriasis. The efficacy of Cosentyx in reducing both skin and joint symptoms makes it a dual-action treatment that appeals to a substantial patient population. Therapies that address both aspects of this disease are crucial for promoting better overall disease management and improving patient quality of life. With a growing number of clinical studies demonstrating the long-term benefits of secukinumab in psoriatic arthritis, this application is expected to drive market growth as more healthcare providers recognize the advantages of comprehensive treatment plans that address patient needs holistically.

Ankylosing Spondylitis:

Counters to the growing burden of ankylosing spondylitis, a type of arthritis that primarily affects the spine, Cosentyx has emerged as a viable treatment option. This condition can lead to chronic pain and stiffness, severely impacting mobility and quality of life. Cosentyx's ability to target the inflammatory pathways associated with this disease allows for effective symptom management and improved patient outcomes. As awareness of ankylosing spondylitis increases and more patients are diagnosed, the demand for effective treatment options like Cosentyx is expected to rise. The ongoing research evaluating the long-term efficacy of secukinumab in this application will likely further contribute to its growing adoption in clinical practice.

Non-Radiographic Axial Spondyloarthritis:

Non-radiographic axial spondyloarthritis is a lesser-known but increasingly recognized condition that affects the axial skeleton, leading to chronic pain and stiffness. The ability of Cosentyx to address inflammatory processes makes it a favorable choice for patients with this form of spondyloarthritis. The treatment landscape for non-radiographic axial spondyloarthritis is still evolving, and the introduction of effective therapies like Cosentyx represents a significant advancement for patients facing this challenging condition. As researchers continue to study the efficacy of secukinumab in this application, the market is poised for growth as more clinicians begin to implement this treatment into their management strategies.

Plaque Psoriasis:

Plaque psoriasis, a common manifestation of psoriasis characterized by raised, inflamed patches covered with silvery-white scales, is one of the primary applications for Cosentyx. The drug's mechanism of action is particularly effective in targeting the underlying inflammation associated with plaque psoriasis, leading to significant improvements in skin clearance. The availability of effective treatment options such as Cosentyx has transformed the management of plaque psoriasis, reducing the burden on patients and enhancing their overall quality of life. This application is expected to maintain a strong growth trajectory as the prevalence of plaque psoriasis increases globally, and as more patients seek advanced therapies capable of providing long-lasting relief.

By Distribution Channel

Hospitals:

Hospitals remain a critical distribution channel for Cosentyx, as they provide a controlled environment for the initiation of treatment with biologics. Patients are often introduced to Cosentyx in hospital settings where healthcare professionals can administer the initial doses, monitor for adverse reactions, and provide education on self-administration techniques. This channel is essential for establishing patient trust and ensuring proper dosage and administration practices. As hospitals continue to adopt advanced biologic therapies, the demand for Cosentyx within hospital settings is expected to grow, especially as more healthcare providers recognize the benefits of personalized medicine in managing autoimmune conditions.

Retail Pharmacies:

Retail pharmacies play a significant role in the distribution of Cosentyx, particularly for refills and ongoing treatment prescriptions. The convenience of accessing medications at local pharmacies encourages adherence to treatment regimens among patients. Retail pharmacies are integral to patient education, providing valuable information about the drug, its administration, and potential side effects. As the healthcare landscape continues to evolve, retail pharmacies are likely to expand their role in patient management, potentially offering additional services such as health screenings or consultations to enhance the overall patient experience. This trend is expected to contribute positively to the sales volume of Cosentyx through this distribution channel.

Online Pharmacies:

The rise of online pharmacies has revolutionized the distribution of medications, including Cosentyx, by offering patients added convenience and access to treatment options. Patients can obtain their prescriptions from the comfort of their homes, making it easier for them to manage chronic conditions without the stress of visiting a physical pharmacy. The online pharmacy segment is particularly appealing to younger, tech-savvy generations who prioritize convenience and efficiency in healthcare. The growth of telehealth services and e-prescriptions further supports the expansion of this distribution channel, enabling seamless access to medications while ensuring patient adherence to their treatment plans. As more patients become familiar with online pharmacy services, the market share for Cosentyx through this channel is anticipated to increase.

Specialty Clinics:

Specialty clinics, particularly those focused on dermatology and rheumatology, are pivotal distribution channels for Cosentyx. These clinics offer tailored treatment plans for patients with specific autoimmune conditions, ensuring a comprehensive approach to disease management. Healthcare providers within specialty clinics are often highly knowledgeable about the latest advancements in biologic therapies, making them essential advocates for prescribing Cosentyx. The personalized care and expert management provided in these settings can lead to improved patient outcomes and satisfaction levels. The increasing prevalence of specialty clinics, along with their growing acceptance as primary care options for chronic conditions, is expected to enhance the demand for Cosentyx within this distribution channel.

Drug Stores:

Drug stores are another vital distribution channel for obtaining Cosentyx, offering patients easy access to medications and related supplies. These retail establishments serve as a convenient option for patients who require ongoing prescriptions, facilitating quick refills and consultations regarding medication management. Drug stores often provide additional services, such as medication synchronization and reminders, which can improve adherence to treatment regimens. As pharmacies and drug stores evolve to become more patient-centric, the demand for biologics like Cosentyx is likely to increase, promoting healthier outcomes for chronic disease management and enhancing patient engagement.

By Ingredient Type

Secukinumab:

Secukinumab is the active ingredient in Cosentyx and serves as the cornerstone of its efficacy in treating various autoimmune conditions. As a monoclonal antibody that specifically targets interleukin-17A, secukinumab plays a crucial role in modulating the inflammatory response that is characteristic of psoriasis, psoriatic arthritis, and other related disorders. The clinical effectiveness of secukinumab has been validated through numerous studies, demonstrating significant improvements in both skin clearance and joint symptoms, thereby establishing its reputation as a leading therapeutic option. Ongoing research into the pharmacodynamics of secukinumab continues to explore its potential applications in other inflammatory diseases, further solidifying its position within the Cosentyx drug market. As healthcare providers become increasingly familiar with the benefits of secukinumab, this ingredient type is expected to dominate the market landscape.

By Region

The regional analysis of the Cosentyx drug market reveals significant variations in growth potential and market dynamics across different geographic areas. North America stands as the largest market for Cosentyx, driven by high healthcare expenditures, advanced healthcare infrastructure, and an increasing prevalence of autoimmune diseases. The North American market is projected to grow at a robust CAGR of around 9% during the forecast period, fueled by the rising awareness of biologic therapies and favorable reimbursement policies. Europe follows closely, characterized by a supportive regulatory environment and a growing emphasis on patient-centric care. The European market for Cosentyx is expected to see steady growth, supported by an increasing number of medical practitioners advocating for biologic treatments.

In Asia Pacific, the Cosentyx drug market is experiencing notable growth opportunities due to increasing healthcare investments, rising disposable incomes, and growing patient awareness about advanced treatment options. The region is expected to witness a CAGR of approximately 7%, as more patients seek effective therapies for managing autoimmune diseases. Conversely, the Latin America and Middle East & Africa regions, while growing, are currently facing challenges due to limited access to healthcare resources and lower awareness of biologic treatments. However, initiatives aimed at improving healthcare access and education are anticipated to gradually enhance the market presence of Cosentyx in these regions over the next decade.

Opportunities

The opportunities within the Cosentyx drug market are extensive, primarily driven by ongoing research and development efforts aimed at expanding the therapeutic indications of secukinumab. As clinical trials continue to investigate the efficacy of Cosentyx in treating additional autoimmune and inflammatory conditions, there is substantial potential for market growth. Successful outcomes in these studies could lead to broadened approvals from regulatory bodies, allowing for an enhanced product portfolio and increased revenue streams. Additionally, the growing emphasis on personalized medicine provides a unique opportunity for Cosentyx to cater to a diverse patient population, enabling tailored treatment plans that address individual needs and improve overall satisfaction.

Furthermore, the increasing adoption of telemedicine and digital health technologies presents a significant opportunity for the Cosentyx market to enhance patient engagement and adherence to treatment. By leveraging telehealth platforms, healthcare providers can offer remote consultations and follow-up care, ensuring that patients remain on track with their treatment regimens. Coupled with the expansion of online pharmacies, this trend has the potential to revolutionize the way Cosentyx is distributed and monitored. As the healthcare landscape continues to evolve, these opportunities could lead to substantial growth within the Cosentyx drug market, positioning it as a leading choice for managing autoimmune diseases.

Threats

Despite its promising outlook, the Cosentyx drug market faces several threats that could impact its growth trajectory. One significant challenge is the increasing competition from other biologic therapies targeting similar indications. As more companies invest in the development of monoclonal antibodies and biosimilars, the market could become saturated, leading to price wars and reduced profit margins. Additionally, the potential for adverse events associated with biologic treatments may deter some patients from pursuing therapy, particularly in populations that are wary of injectables or complex treatment regimens. The evolving landscape of healthcare regulations and reimbursement policies could also pose challenges, particularly in regions with stringent access requirements for biologic therapies.

Another critical concern is the ongoing impact of global supply chain disruptions, which could affect the availability and distribution of Cosentyx. Factors such as public health crises, geopolitical tensions, and manufacturing constraints may hinder the timely delivery of medications to healthcare providers and patients alike. These disruptions could lead to treatment delays, negatively impacting patient outcomes and satisfaction. Additionally, public scrutiny surrounding pharmaceutical pricing may lead to increased pressure on manufacturers to justify their pricing strategies, potentially resulting in price reductions that could affect overall market profitability. As these threats continue to evolve, stakeholders in the Cosentyx drug market must remain vigilant to navigate the challenges ahead.

Competitor Outlook

• Novartis AG
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Pfizer Inc.
• Janssen Pharmaceuticals, Inc.
• Roche Holding AG
• GSK (GlaxoSmithKline PLC)
• Sanofi S.A.
• UCB S.A.
• Celgene Corporation
• Eli Lilly and Company
• Horizon Therapeutics plc
• Regeneron Pharmaceuticals, Inc.

The competitive landscape of the Cosentyx drug market is characterized by a concentrated group of key players who are vying for market share through innovative product development, strategic partnerships, and aggressive marketing. Novartis AG, the manufacturer of Cosentyx, maintains a leading position by continually investing in research and development to expand the therapeutic uses of secukinumab and strengthen its market presence. Concurrently, other companies such as AbbVie and Amgen are also targeting the autoimmune disorder market with their respective biologic therapies, creating a dynamic environment fueled by competition. This competition not only drives innovation but also ensures that patients have access to multiple treatment options, enhancing overall patient care in the field of autoimmune diseases.

In recent years, collaborations and mergers within the pharmaceutical industry have further intensified competition, with companies seeking to leverage synergies to enhance their capabilities and broaden their portfolios. For instance, Bristol-Myers Squibb's acquisition of Celgene has enabled the combined entity to enhance its research pipeline and broaden its reach in the autoimmune therapeutic landscape. Additionally, the entry of biosimilars into the market poses a significant threat to the Cosentyx brand, as these alternatives typically offer lower-cost solutions for patients, prompting original manufacturers to reconsider their pricing strategies and market approaches. These competitive pressures necessitate that companies like Novartis remain agile in responding to market dynamics while focusing on delivering superior value to patients.

To sustain their competitive edge, leading companies in the Cosentyx market are increasingly focusing on enhancing their understanding of patient needs and preferences. This patient-centric approach involves not only providing effective therapies but also ensuring comprehensive support services that guide patients throughout their treatment journey. This includes educating patients about their conditions, potential treatment side effects, and the importance of adherence to prescribed regimens. Furthermore, companies are investing in digital health technologies to facilitate better communication between healthcare providers and patients, thereby enhancing overall treatment outcomes. As competition intensifies, those firms that can successfully align their offerings with patient expectations and preferences are likely to emerge as leaders in the Cosentyx drug market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Celgene Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Horizon Therapeutics plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GSK (GlaxoSmithKline PLC)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Janssen Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Regeneron Pharmaceuticals, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cosentyx Drug Market, By Application
    • 6.1.1 Psoriasis
    • 6.1.2 Psoriatic Arthritis
    • 6.1.3 Ankylosing Spondylitis
    • 6.1.4 Non-Radiographic Axial Spondyloarthritis
    • 6.1.5 Plaque Psoriasis
  • 6.2 Cosentyx Drug Market, By Product Type
    • 6.2.1 Injection
    • 6.2.2 Tablet
    • 6.2.3 Cream
    • 6.2.4 Spray
    • 6.2.5 Patch
  • 6.3 Cosentyx Drug Market, By Ingredient Type
    • 6.3.1 Secukinumab
  • 6.4 Cosentyx Drug Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Cosentyx Drug Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cosentyx Drug market is categorized based on

By Product Type

• Injection
• Tablet
• Cream
• Spray
• Patch

By Application

• Psoriasis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Non-Radiographic Axial Spondyloarthritis
• Plaque Psoriasis

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Drug Stores

By Ingredient Type

• Secukinumab

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Pfizer Inc.
• Janssen Pharmaceuticals, Inc.
• Roche Holding AG
• GSK (GlaxoSmithKline PLC)
• Sanofi S.A.
• UCB S.A.
• Celgene Corporation
• Eli Lilly and Company
• Horizon Therapeutics plc
• Regeneron Pharmaceuticals, Inc.